Moxonidine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page

Moxonidine

Imidazoline Receptor Agonists

GB MHRA

Drug class: Imidazoline Receptor Agonists
Availability: See label
Markets covered: 1
Products on record: 27

Overview

Moxonidine is an active pharmaceutical ingredient in the Imidazoline Receptor Agonists group (C02AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	27	May 22, 2026

GBUnited Kingdom· MHRA

27 products

Uses

GBOfficial regulatory label· revised April 10, 2026[1]

Moxonidine is indicated in adults for treatment of mild to moderate essential hypertension.

How to take

Sources & citations

[1]MHRA (UK) · PL045690622 · revised April 10, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 10, 2026[1]

Most frequent side effects reported by those taking moxonidine include dry mouth, dizziness, asthenia and somnolence. These symptoms often decrease after the first few weeks of treatment. Undesirable Effects by System Organ Class (observed during placebo-controlled clinical trials with n=886 patients exposed to moxonidine resulted in frequencies below): *there was no increase in frequency compared to placebo Very common (>1/10) Common (>1/100, <1/10) Uncommon (>1/1,000, <1/100) Very rare (<1/10,000) Endocrine disorders Gynaecomastia, impotence and Very common (>1/10) Common (>1/100, <1/10) Uncommon (>1/1,000, <1/100) Very rare (<1/10,000) loss of libido Psychiatric disorders Altered thought processes, insomnia Anxiety, nervousness, anorexia Nervous system disorders Sleep disturbances, headache*, dizziness, vertigo, somnolence Sedation, syncope* Eye disorders Dry, itching or burning sensation of the eye Ear and labyrinth disorders Tinnitus Cardiac disorders Bradycardia Vascular disorders Vasodilatation Hypotension (including orthostatic), paraesthesia of extremities, peripheral circulation disorders Gastrointestinal disorders Dry mouth Diarrhoea, nausea / vomiting / dyspepsia*, constipation and other gastrointestinal disorders Hepatobiliary disorders Hepatic reactions Skin and subcutaneous tissue disorders Rash / Pruritus, Angioedema Musculosketal and connective tissue disorders Back pain Neck pain General disorders and administration site conditions Asthenia Oedema of different location, leg weakness, fluid retention, Very common (>1/10) Common (>1/100, <1/10) Uncommon (>1/1,000, <1/100) Very rare (<1/10,000) parotid pain *there was no increase in frequency compared to placebo Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

GBOfficial regulatory label· Warnings and precautions· revised April 10, 2026[1]

Cases of varying degrees of AV block have been reported in the post-marketing setting in patients undergoing moxonidine treatment. Based on these case reports, the causative role of moxonidine in delaying atrioventricular conduction cannot be completely ruled out.
Therefore, caution is recommended when treating patients with a possible predisposition to developing an AV block. When moxonidine is used in patients with 1st degree AV block special care should be exercised to avoid bradycardia. 3).
When moxonidine is used in patients with severe coronary artery disease or unstable angina pectoris special care should be exercised due to the fact that there is limited experience in this patient population. Due to lack of clinical evidence supporting safe use in patients with co-existing moderate cardiac insufficiency, moxonidine should be administered with caution in these patients.
Caution is advised in the administration of moxonidine to patients with renal impairment as moxonidine is excreted primarily via the kidneys. In these patients careful titration of the dose is recommended, especially at the start of therapy.
3 mg daily for patients with severe renal impairment (GFR<30 ml/min) if clinically indicated and well tolerated. If moxonidine is used in combination with a β-blocker, and both treatments have to be discontinued the β-blocker should be discontinued first, and, then moxonidine after a few days.
So far, no rebound effect on blood pressure has been observed after the discontinuation of treatment with moxonidine. However, it is advisable not to stop taking moxonidine abruptly, but to reduce it gradually over a period of two weeks.
The elderly population may be more susceptible to the CV effects of blood pressure lowering drugs. Therefore therapy should be started with the lowest dose and dose increments should be introduced with caution to prevent the serious consequences these reactions may lead to.
Moxonidine contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations